Use of anti-obesity drugs among college students  by e Martins, Maria do Carmo de Carvalho et al.
ORIGINAL ARTICLE
SUMMARY
Objective: To evaluate the use of anti-obesity drugs among students attending a public 
university. Methods: This was a cross sectional random study of 664 college students. 
Drug use, socioeconomic, and anthropometric variables were observed. Body mass in-
dex (BMI) and waist circumference (WC) were classified according to World Health Or-
ganization criteria. Results: Current or previous use of anti-obesity drugs was reported 
by 6.8% of students. Amphetamine and sympathomimetic amines (40.5%) were the most 
commonly used drugs. Among those who reported use of anti-obesity agents, 62.2% 
were female. Only 31.1% of medications were prescribed by doctors. Mean BMI and 
WC were higher among students reporting the use of such drugs, but 47% of them were 
classified as eutrophic by BMI, and 76.5% had normal WC measure. Conclusion: The 
use of anti-obesity drugs among college students is of concern, particularly due to 
the high proportion of drug use without indication or prescription.
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INTRODUCTION
Obesity is considered a global epidemic1, which is recog-
nized as a risk factor for many undermining and high social 
cost diseases, such as type 2 diabetes, hypertension, stroke, 
heart disease, dyslipidemia, and some types of cancer2.
The World Health Organization estimates that in 2015 
approximately 2.3 billion adults will be overweight and 
more than 700 million will be considered obese3. In Brazil, 
overweight and obesity prevalence are universally growing 
and reached in 2002-2003 about 40% and 12.7%, respec-
tively, according to estimates of a Brazilian survey (Pesquisa 
de Orçamentos Familiares [POF]4) of the adult population. 
In the city of Teresina, according to estimates of the same 
survey, the overweight and obesity prevalence for male and 
female were 41.5%-7.8% and 36.3%-9.5% (respectively). 
Pharmacological treatment of obesity is indicated when 
the individual has body mass weight (BMI)>30kg/m2 
or disease associated with overweight, BMI>25kg/m2 in 
situations where treatment with diet, physical activity, and 
behavioral modifications was unsuccessful5. Drug therapy 
for obesity includes the use of agents involved in the con-
trol mechanism of energy intake, or agents related to the 
shi of normal nutrient metabolism or that increase ener-
gy expenditure6. The anti-obesity agents most commonly 
used are sibutramine and orlistat, both available in clinical 
practice for nearly a decade7. Sibutramine blocks the reup-
take of norepinephrine and serotonin reducing food in-
take, and also stimulates thermogenesis in brown adipose 
tissue in animals8. Orlistat is a more stable and partially 
hydrolyzed analog of lipstatin (tetrahidrolipstatin), which 
acts by inhibiting gastrointestinal lipases through irrevers-
ible binding at the active site of lipase by covalent binding9.
In the prevailing epidemiological context of high 
prevalence of overweight and the fact that today the ste-
reotype of beauty is the kind of lean and lanky body10, a 
high consumption of anorexigens has been observed in 
Brazil since 1988, estimated at 10 daily doses statistically 
defined (S-DDD) per thousand inhabitants11. According to 
the Report of the International Narcotics Control Board 
(INCB), there was an increase of 500% in the consumption 
of anorexigens in Brazil since 1998, noting also that the 
consumption of stimulants in Brazil, mainly as anorexi-
gens, is one of the highest worldwide12, reaching in 2005 
the highest rates of stimulants consumption calculated per 
1,000 inhabitants (per day) in the Schedule IV of the 1971 
Convention (12.5 S-DDD)13.
The reasons for the high consumption of anorexigens 
reect not only the increased prevalence of obesity and 
overweight in Brazil over the past 40 years, but also the 
irrational and wide spread use of these and other drugs in 
the country14. 
The young adult population, especially college students, 
stands out particularly with the role of higher education in 
the adoption of preventive actions and plans to give the un-
dergraduate an opportunity to contribute to the commu-
nity they belong to15. From this perspective, a study of this 
population group acquires greater relevance when the goal 
is a true assessment of drug use in a group of young and 
opinion-maker individuals, which enables the provision of 
subsidies for future preventive measures in this population. 
Our aim was to evaluate the use of drugs for weight loss 
among students in a Brazilian federal university.
METHODS
This work was part of the research project entitled “Socio-
economic, nutritional, and health profile of students at the 
Universidade Federal do Piauí (UFPI) – Brazil” and con-
sisted of a descriptive cross-sectional study, with a proba-
bilistic sample of 664 students. Sample size was calculated 
assuming a confidence interval of 95% and finite popula-
tion of 11,152 students, according to the formula used by 
Martins16 for estimates of large sample proportion, and the 
margin of error found was 3.75%. The sample was pro-
portional to the number of students attending the course, 
course period, and teaching center of UFPI (Center for 
Agricultural Sciences, Education Sciences Center, Center 
for Humanities and Arts, Natural Sciences Center, Cen- 
ter for Health Sciences, and Technology Center).
The instrument used for data collection was a ques-
tionnaire to attain information on socio-economic (age, 
sex, marital status, family income, and the mothers’ level 
of education) and anti-obesity drug use. In addition, an-
thropometric measurements of body weight were taken 
(determined on a digital scale Plenna Acqua SIM-09190, 
with measuring capacity of 180íkg and variation of 0.1íkg), 
height (blood pressure anthropometric tape measure with 
a precision of 1ímm), and hip circumferences (measured 
with a fiberglass tape with precision of 1ímm).
Measurements of weight, height, and waist circum-
ference were conducted with students barefoot, wearing 
light clothes and accessories that would not interfere with 
measurements, according to the recommendations in the 
Manual of techniques and procedures of the Brazilian 
Ministry of Health17. Waist circumference was measured 
at the midpoint between the last rib and the iliac crest, and 
waist and hip circumference measured at the largest cir-
cumference of the buttocks, with the tape held in a hori-
zontal plane, without pressing soí  tissues17.
Overall nutritional status was classified using the BMI 
based on the cutoí  points proposed by WHO18, with 
normal weight defined as BMIí >í 18.5 and <í 25í  kg/m²; 
overweight as BMIíí í25 and <í30íkg/m²; and obesity as 
BMIíí í30íkg/m². The term overweight was used for group-
ing overweight or obese individuals (i.e. individuals with 
BMIíí í25íkg/m²).
Waist circumference (WC) was used in order to iden-
tify the distribution pattern of body fat using the cut-oí s 
defined by Lean et al.19 and currently recommended by 
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WHO18, considering adequate or normal WC <80cm 
for women and <94cm for men, and with cut-o points 
described in action levels, both in clinical use and in 
health promotion programs, as follow: action level 1 or 
increased risk for morbidities associated with obesity 
(WC between 80 and 88cm for women and between 94 
and 102cm for men), in which the individual should be 
advised to stop gaining weight and adopt a healthy life-
style; and level 2 or very increased risk (88 for wom-
en and 102 for men), in which the individual should 
seek help from health care professional for weight loss 
and investigation of other risk factors. The waist-hip ra-
tio (dimensionless) considered values  higher than 0.8 in 
women and 0.9 in men18.
The study protocol was approved by the Ethics Com-
mittee of the Universidade Federal do Piauí. Aer elu-
cidation about the study objectives and possible ben-
efit and risks tied to his execution, all study participants 
signed an informed consent.
Data were processed in 5.020 EpiInfo and BioEstat 
6.04b21 programs. Statistical analysis for associations 
between variables was performed by chi-square test of 
association, and the unpaired t-test was used for mean 
comparisons. The level of significance was set at 5% 
(p<0.05).
RESULTS
A total of 664 students were enrolled in the study, and 
6.8% of them were using or have used anti-obesity drugs, 
with no statistically significant dierences between sexes 
(Table1). Only one third of these drugs was prescribed by 
doctors, especially among females (p=0.02). The drugs 
most used were amfepramone, fenproporex hydrochlo-
ride, and sibutramine, which together accounted for 40.5% 
of the drugs used. Moreover, in the twelve months pre-
ceding the study, 17.8% of university students were using 
drugs for obesity treatment without prescription (Table1).
The family income of 2.6% of the students was less than 
or equal to one minimum wage, however, more than half 
(55.1%) of respondents had a family income above five 
minimum wages. Investigation of marital status showed 
that 88.7% of students were single, and the largest propor-
tion of non-drug users for weight loss (p=0.01) was among 
those who had mothers with higher education (Table2).
Table 1 – Use of anti-obesity drugs among students in a Brazilian public university, according to sex
Sex p-value

r2
Female Male Total
Variables n % n % n %
Use or have used weight-loss drugs?*
Yes 28 8.6 17 5.8 45 6.8 0.21
No 326 91.4 293 94.2 619 93.2
Total 354 100.0 310 100.0 664 100.0
Who recommended the medication? **
Physician 12 42.8 2 11.7 14 31.1 0.02
Relative, friend, own initiative, others, 
or not stated 
16 57.2 15 88.3 31 68.9
Total 28 100.0 17 100.0 45 100.0
What anti-obesity drug do you use
or used? **
Amfepramone 1 3.6 1 5.9 2 6.2 0.48
Fenproporex hydrochloride 4 14.3 1 5.9 5 15.6
Sibutramine 5 17.5 1 5.9 6 18.7
Other or not stated 18 64.6 14 82.3 32 59.5
Total 28 100.0 17 100.0 45 100.0
Did you use anti-obesity drug in the last year  
without medical indication ou prescription? **
Yes 4 14.3 4 23.5 8 17.8 0.25
No 17 60.7 6 35.3 23 51.1
Not stated 7 25.0 7 41.2 14 31.1
Total 28 100.0 17 100.0 45 100.0
*Question asked to all study participants. ** Question asked to individuals who use or have used weight-loss drugs.
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The students’ mean age was 23.2years and no dier-
ence was observed between the ages of individuals who 
reported use of anti-obesity drugs and those who have 
never used (p=0.07). There was no association between 
waist-hip ratio (WHR) and systolic or diastolic blood 
pressure between these groups. Although the mean BMI 
(23.5kg/m²), waist circumference (79.5cm), and hip cir-
cumference (98.9cm) were significantly higher (p<0.05) 
in college students who were using or have used anti-obe-
sity drugs (Table3), the proportion of students reporting 
use of anti-obesity drugs classified as normal by BMI was 
47%, and the classification for both WC and WHR 
was 76.47%. Classification of overweight and obesity by 
BMI were 29.42% and 11.76%, respectively. The preva-
Table 2 – Socio-economic characteristics of students at a public university, according to the use of anti-obesity drug
Students p-value
Variables n c* % r2
Family income (minimum wage)
≤ 1 17 2 4.4
0.58
> 1 e ≤ 3 140 7 15.6
> 3 e ≤ 5 141 12 26.7
> 5 e ≤ 10 181 11 24.4
≥ 10 146 12 26.7
Not stated 39 1 2.2
Total 664 45 100.0
Marital status
Married 47 3 6.7
0.92
Single 589 39 86.7
Divorced 16 2 4.4
Others 12 1 2.2
Total 664 45 100.0
Mother’s education
College degree or more 220 9 20.0
0.01Incomplete higher education 
or less
427 32 71.1
Not stated 17 4 8.9
Total 664 45 100.0
n, number of students; c, number of cases (users).
*It was considered user the student who reported to be using or have made  use of anti-obesity drugs.
Students Users* p-value
t testVariables Mean
Standard 
deviation
Mean
Standard 
deviation
Age (years) 23.2 4.0 23.1 4.2 0.07
SBP (mmHg) 117.8 12.1 117.5 8.5 0.60
DBP (mmHg) 76.3 9.6 76.4 7.3 0.90
BMI (kg/m²) 22.6 3.4 23.5 3.8 0.0008
Waist circumference (cm) 77.6 9.7 79.5 9.7 0.01
Hip circumference (cm) 97.6 7.8 98.9 7.7 0.03
Waist-hip ratio 0.78 0.08 0.79 0.06 0.29
SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index. 
*It was considered user the student who reported to be using or have made  use of anti-obesity drugs.
Table 3 – Age, blood pressure, and anthropometric characteristics of students in a public university, according to the use 
of anti-obesity drugs
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lence of abdominal obesity classified by waist circumfer-
ence was 5.88%. Based on the anthropometric assessment, 
among those who reported medical indication, the use of 
anti-obesity medication was justified in 66.67%.
Restlessness, irritability or nervousness, insomnia, 
malaise or dizziness were the most common side eects 
among participants who reported using anti-obesity drugs 
(21.4%). 
DISCUSSION
A report released by the International Narcotics Control 
Board (INCB), an organ reporting to the Organization of 
United Nations (ONU), showed that there was a 500% in-
crease in consumption of anorexigens in Brazil since 199822. 
In this study, 6.8% of students were using or have used 
drugs for weight loss. These results are similar to those 
(6.5%) found in an institution for rehabilitation of children 
and juvenile delinquents in Porto Alegre, RS23, and  are su-
perior to data from the 2005 Household Survey on the Use 
of Psychotropic Drugs in Brazil, involving the 108 largest 
Brazilian cities, which showed that 4.1% of respondents 
have already used appetite suppressants24. On the other 
hand, larger proportions were found in a study by Sichieri 
et al.25 of women aged 35 and older, living in permanent 
private households in the municipality of Rio de Janeiro in 
which the use of some formulas at least once was reported 
by 34% of women, with greater frequency among younger 
and obese women with higher socioeconomic level. The 
high consumption of these substances by the college stu-
dents of Piauí supports the panorama of concern about 
the Brazilian position in the world ranking of these drugs 
consumption12.
Among the anti-obesity agents commonly used by re-
spondents were amfepramone, fenproporex hydrochloride, 
and sibutramine. A sobering fact concerning the use of 
these drugs is that only one third of students reported the 
use of prescription drugs and medical guidance, which re-
fers to the great problem of self-medication and the risks as-
sociated with it. Among the causes of the indiscriminate use 
of drugs by the population, especially in self-medication, are 
the multitude of pharmaceutical products in the market and 
its massive advertising, the shy awareness campaigns about 
the possible health problems resulting from this practice, as 
well as drug information transmitted by “word of mouth”, 
the internet or other media26, and the psychosocial prob-
lems caused by the “dictatorship of thinness”10.
In addition to the problem of self-medication, the ir-
rational use of appetite suppressants and a series of im-
proper practices regarding its prescription in Brazil14 – and 
possible medical malpractice in prescribing psychotro-
pic medication27 – point out the need for a comprehen-
sive review of the government’s control system of these 
substances14. In this sense, Carneiro et al.22, analyzing 
168,237 prescriptions and notifications of prescriptions 
dispensed, evidenced the poor quality of notifications and 
highlighted the indiscriminate and irrational use of an-
orexigens, revealing how crucial it is the improvement of 
market regulation.
This whole scenario should alert the regulatory agen-
cies regarding the high frequency of side eThects caused by 
appetite suppressants usage, as this was one of the reasons 
(for a long time) why the pharmacological treatment of 
obesity was seen as a controversial treatment option, sub-
ject to considerable criticism9.
Feelings of restlessness, irritability, nervousness, in-
somnia, malaise, dizziness, and anxiety have been de-
scribed as the side eThects most reported by the students 
interviewed in this study. Massuia et al.10, investigating 
the use of weight-loss schemes associated with the use 
of drugs with or without prescription among 230 college 
students of São João da Boa Vista, SP, found that the side 
eThect of such medications was the main reason leading to 
discontinuation of its use.
The socioeconomic profile of study participants was 
similar to that found in other studies with regard to family 
income and marital status28,29, and the anorexigen drugs 
used were also similar14,22,30. Furthermore, there was a 
higher proportion of non-users among those who had 
mothers with higher education degree.
Another fact worth mentioning is the diTherence in 
consumption pattern of anorexigen drugs between men 
and women31. In absolute numbers, the highest proportion 
of female users (62.2%) found in this study agrees with the 
national trend14 and also with other studies conducted 
with students10,22,29.
The diTherence in consumption of anorexigens between 
the sexes is probably based on female and male diTherences 
regarding body dissatisfaction32, quantitatively greater in 
female33, and the diTherence in usage purpose between the 
sexes, as demonstrated by Barcellos et al.34 In this sense, 
Nappo et al.35 concluded that the use of drugs such as am-
phetamines in Brazil is particularly prevalent among wom-
en, and its use is strongly related to the culture of thinness 
as a symbol of beauty. In addition, the knowledge that 90% 
of the individuals who develop serious eating disorders are 
adolescents and young women may have relevance to the 
explanation of this fact36.
It is also important to note that the mean BMI, WC, and 
HC were significantly higher in students who were using 
or have used drugs for weight loss. This finding is probably 
justified by the fact that many people start consumption 
because they are overweight. In addition, this observation 
corroborates the fact that body image33 has relevance in the 
use of such medications, but may also reveal the ineThective-
ness of such drugs when used recklessly and irrationally.
Drugs such as sibutramine, for example, reduce body 
weight by only 4-6%37, a mean similar to that obtained by 
interventions involving only low-energy diets38. In addi-
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tion, the pharmacological treatment of obesity when dis-
continued or interrupted results in body weight regain9,39.40. 
Note also that prolonged therapy with sibutramine for 
more than two years is associated with a mean weight re-
covery of approximately half of the initial weight loss41.
The results presented here showed high prevalence of 
appetite suppressant users or former users, and the most 
commonly used drugs were amphetamines and sympatho-
mimetic amines. We also found a considerable proportion 
of these non-prescription drugs been used by college stu-
dents of Piauí, particularly among the female group of this 
population and those with overweight. 
CONCLUSIONS
The proportion of anti-obesity drugs used among college 
students is worrisome, particularly considering the high 
proportion used without indication or prescription. Thus, 
it is clear the need for reassessment of control policies and 
regulations so far adopted for these products in the coun-
try, a fact now being discussed by the Brazilian National 
Agency of Sanitary Vigilance, along with the medical pro-
fessionals and various governmental and non-governmen-
tal organizations regarding the use of psychoactive drugs
This study demonstrates the importance of implement-
ing health education programs targeted at college students, 
aiming to clarify the risks and complications caused by the 
indiscriminate use of anorexigens and other drugs.
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